Background: Pancreatic cancer is the fourth leading cause of cancer deaths worldwide, a particularly lethal cancer, with the majority of cases dead inside the first year. Mortality statistics have barely changed in over fifty years. Case history: This case history recounts the atypical presentation of a rare pancreatic adenocarcinoma as an aggressive pancreatic pseudocyst, that required multiple drainage/ablative surgeries, mostly in a short time span of 3 months, and recurring. Biopsy revealed its true nature as a rare mucinous adenocarcinoma, by then stage 4 with peritoneal metastases, therefore deemed inoperable, the worst prognosis. Palliative FOLFOX chemotherapy followed by SABR radiotherapy were proposed, with the PARP inhibitor, Olaparib planned as maintenance treatment. These therapies were not expected to radically change the prognostic outlook. However, on compassionate grounds, some experimental therapies, were combined, intended to synergise with the palliative protocols. These therapies included daily high dose methylcobalamin injections, twice weekly, intravenous high dose, vitamin C, liposomal alpha lipoic acid, a ketogenic diet, anti-cachectic medium chain triglyceride oil, high dose vitamin D and a functional food containing colostrum, naturally high in the activated vitamin D binding protein, as well as in lactoferrin, haptocorrin and other immune modulating components. In addition, a quartet of off label drugs, which early research shows have some anti-cancer actions, were prescribed: doxycycline, metformin, atorvastatin and the antiprotozoan drug, mebendazole. Outcome: The patient responded well to these protocols, and was on the road to recovery within 6 months, and in complete remission for almost two years now. The rationale for such therapies is reviewed and analysed, and weighting is assessed for the individual therapies. We propose that such an integrative combination of standard/non standard, research based therapies may provide a blueprint for survival in pancreatic cancer that deserves formal clinical trials. &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&